Clinical Trial

Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy and safety of low-dose versus standard-dose rivaroxaban anticoagulation therapy in elderly patients with atrial fibrillation.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-10-25; most recent amendment 2024-09-11.
Status change: Not Yet Recruiting → Recruiting 2024-09-11
Trial Details
NCT Number NCT06108414
Lead Sponsor China National Center for Cardiovascular Diseases
Conditions Atrial Fibrillation, Anticoagulant Adverse Reaction, Stroke, Major Adverse Cardiac Events
Enrollment 4,374 participants
Start Date 2024-09-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-19